CD274 and non-small cell lung carcinoma: As the efficacy of immunotherapy in advanced or metastatic NSCLC has been demonstrated (19, 20), attention has naturally turned toward the use of programmed cell death receptor-1 (PD-1)/PD-L1 inhibitors in early-stage NSCLC (21).